Norstella

Citeline Podcasts

Business EN ↓ 651 episodes

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Be sure to visit the podcast's website and support the creator: www.citeline.com

Author

Norstella

Category

Business

Podcast website

www.citeline.com

Latest episode

Nov 19, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Scrip's Five Must-Know Things - 10 December 2024 10.12.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 December 2024. In this episode: Zepbound bests Wegovy; Novartis and PTC’s Huntingdon’s deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic’s hopes for MS drug. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must...

Datamonitor Healthcare Podcast: Psychedelic Symposium at the University of Wisconsin-Madison 10.12.2024

Summer Colling speaks with Emma Wille about the Psychedelic Symposium at the University of Wisconsin-Madison and what the future of psychedelic therapeutics could look like.

Arialys Therapeutics: Treating Autoimmune Neuropsychiatric Diseases 09.12.2024

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company’s monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.

Drug Fix: COVID-19 Vaccine EUAs In Danger, DOGE And US FDA, New 340B Rebate Pricing Models 06.12.2024

Pink Sheet reporter and editors discuss potential threats to the COVID-19 vaccine pediatric indications under the Trump Administration (:24), the DOGE commission’s search for spending cuts and its impact on the FDA (12:52), as well as a new 340B rebate pricing model that some pharma companies are implementing to contain the program’s costs (22:52). More On These Topics From The Pink Sheet Pediatri...

November 2024 Datamonitor Healthcare Podcast: Bispecific Antibodies in Oncology 05.12.2024

Emma and Summer meet with oncology analysts Neha Anand and David Dahan, to discuss an emerging class of drugs: bispecific antibodies.

Treating Rare Diseases With tRNA 04.12.2024

In this episode of the In Vivo podcast, Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases, including those stemming from nonsense mutations.

Conference Catch-Up: BIO-Europe 2024 03.12.2024

Biopharma is evolving through collaboration, early-phase deal-making and innovation in precision medicine and AI. At BIO-Europe, Norstella's subject matter experts explored key trends shaping the industry, from market access strategies to sustaining growth through partnerships. In this episode, Izabela Chmielewska, Kevin Grogan, and Natasha Choukkar discuss takeaways – from advancing personalized...

Scrip's Five Must-Know Things - 2 December 2024 02.12.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 29 November 2024. In this episode: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India. https://insights.citeline.com/scrip/podcasts/quick-listen-scrips-five-must-know-things-GIXQTTF...

Scrip Awards Podcast, Ep2: 2024 Awards Preview & Verona Pharma Interview 28.11.2024

A preview of the 2024 Scrip Awards and an interview with last year’s Executive of the Year, David Zaccardelli, CEO of Verona Pharma.

Scrip's Five Must-Know Things - 25 November 2024 22.11.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 22 November 2024. In this episode: Novo’s semaglutide looks good in NASH; J&J’s psoriasis drug hits multiple Phase III goals; NASH competition gets serious; China dominates APAC and increasingly global trials; and why has M&A decreased in 2024. https://insights.citeline.com/scrip/podcasts/quick-listen-scri...

Drug Fix: Trump’s Potential Impact On FDA User Fees, Dr. Oz’s Potential Impact On CMS 22.11.2024

Pink Sheet reporter and editors discuss concerns that the incoming administration could try to influence the upcoming FDA user fee reauthorization (:30), as well as the changes Dr. Mehmet Oz, President-elect Donald Trump’s controversial selection of to run the US Centers for Medicare and Medicaid Services, could impose if confirmed (22:35). #pharma #business More On These Topics From The Pink Shee...

Scrip's Five Must-Know Things - 18 November 2024 18.11.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 15 November 2024. In this episode: muscling into the obesity market; AbbVie’s schizophrenia failure; Bayer will not take risky bets; generally strong Q2 for Japanese majors; and AstraZeneca juggles China and growth questions. https://insights.citeline.com/scrip/podcasts/quick-listen-scrips-five-must-know-t...

Drug Fix: Trump Picks Robert F. Kennedy Jr. To Lead HHS, How Could He Disrupt FDA? 15.11.2024

Pink Sheet reporter and editors, and guest Michael McCaughan of Prevision Policy, continue the discussion of Donald Trump’s potential impact on the FDA, including how Robert F. Kennedy Jr. could change the agency as head of HHS (:37), whether lasting changes are coming to the FDA (13:00), and Commissioner Robert Califf’s request that industry help preserve the agency status quo (18:18). More On Th...

Scrip M&A Podcast: Why Did Biopharma M&A Metrics Decline During Q2 And Q3 14.11.2024

Scrip senior writer Joseph Haas discusses recent merger-and-acquisition activity in the biopharma sector with Gerardo Ubaghs, CFO of Frontier Medicines, and Jason Silvers, CFO of Generate Biomedicines. The panel looks at why M&A activity metrics declined during both the second and third quarters despite a strong start to the year and apparent positive conditions for dealmaking, as well as what imp...

Using AI To Predict Our Immune Responses 11.11.2024

In the latest episode of the In Vivo podcast, Noam Solomon, co-founder and CEO of Israeli-American biotech Immunai explains how his company is mapping the immune system and using AI to predict individual immune responses to drugs. Noam also discusses the company's own acquisitions, partnerships, the differences between innovation and invention, artificial biomedical intelligence (ABI) and barriers...

Scrip's Five Must-Know Things - 11 November 2024 11.11.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 8 November 2024. In this episode: what Trump might mean for pharma; Novo’s semaglutide hits mark in NASH; AstraZeneca leads the way in clinical trials; Viking’s weight loss data excite; and how to speed up MLR reviews. https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-D4FI3E5BCN...

Conference Catch-Up: Navigating the Evolving CDMO Landscape 10.11.2024

Contract development and manufacturing organizations (CDMOs) are reshaping pharmaceutical production, playing a pivotal role in supply chain stability and driving innovation. In today’s fast-evolving environment, CDMOs help life sciences companies enhance speed, flexibility, and efficiency, which ultimately advances access to life-saving therapies. Norstella provides tailored insights, tools, and...

Drug Fix: How Will Trump’s Second Term Impact The US FDA? 08.11.2024

Pink Sheet reporter and editors discuss potential changes that the incoming Trump Administration could make on the FDA, as well as worries about political interference in decision-making, and policy and staffing changes. More On These Topics From The Pink Sheet US FDA’s Drug Approval Norms Could Be Upended In Second Trump Term: https://insights.citeline.com/pink-sheet/legislation/elections/us-fdas...

Digital Health Roundup: GE HealthCare On AI At HLTH; EU AI Act, Click Therapeutics 07.11.2024

In this week’s Digital Health Roundup, Medtech Insight’s Marion Webb talks about her interview with GE HealthCare’s chief AI officer Parminder Bhatia at HTLH on his vision for AI in health care. Natasha Barrow discusses her interview with Owkin on the EU AI Act and highlights Click Therapeutics’ latest clinical results.

Scrip's Five Must-Know Things - 5 November 2024 05.11.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 1 November 2024. In this episode: Lilly plans DTC tirzepatide ads; Pfizer’s Bourla defends strategy; expert views from BioFuture; China retains attractions for some; and AbbVie’s Aliada acquisition. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

【3分で解説 世界のファーマ】第22回 AD治療、費用対効果に悩む英国 (Japanese-language podcast) 29.10.2024

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。 今回取り上げた記事はこちら 「Déjà Vu In England: Lilly’s Alzheimer’s Drug Kisunla Gets MHRA Yes, But NICE Says No(邦訳:アルツハイマー治療薬ケサンラ承認で議論再び、薬価負担に悩む英国)」 URL:  https://insigh...

Scrip's Five Must-Know Things - 28 October 2024 28.10.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 25 October 2024. In this episode: Merck & Co’s Modifi acquisition; scenarios for new obesity drugs; Astellas gets US approval for claudin drug Vyloy; iTeos builds TIGIT lead; and execs discuss AI in clinical trials. https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-YMAHSAK2FBBKP...

Conference Catch-Up: The Rise of Digital Therapeutics (Part 2) 26.10.2024

Health technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving treatments to patients. In particular, digital therapeutics have become a prominent area of focus due to their potential to improve outcomes while reducing patient burden. Norstella continues to be proponent for these innovative technologies, partnering with organizations to launch...

October 2024 Datamonitor Healthcare Podcast: Insights from ESMO 21.10.2024

Emma and Summer meet with oncology analysts Neha Anand, Anna Simmons, and Nkiru Ibeanu, to share insights from the European Society of Medical Oncology (ESMO) conference.

Scrip's Five Must-Know Things - 21 October 2024 21.10.2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 18 October 2024. In this episode: J&J looks to Tremfya as Stelara declines; Pfizer’s Hympavzi may find hemophilia B niche; big pharma’s cell and gene therapy realities; M&A took a holiday in Q3; and last rites for Sanofi’s RIPK1 drug. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-thing...

Listen to the Citeline Podcasts podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.